Incorporates an active component that will significantly shorten the treatment duration of MPE compared to current catheter devices.
A user-friendly design to promote patient independence, comfort and quality of life.
Reduces the costs associated with long-term home drainage and acute readmissions to hospital.
Posted in News by Michelle Tierney
19th March, 2020
In March 2020, SymPhysis Medical were named as finalists in the annual Futurescope One2Watch competition. FutureScope is Ireland’s leading business innovation event, and the One2Watch competition seeks to find Ireland’s most...
Read more
Posted in News by Symphysis Medical
2nd December, 2019
The IBYE competition, now in its fifth year, is a nationwide youth enterprise initiative to support 18-to-35 year olds with an innovative business idea, new start-up or established business. In...
Read more
Posted in News by Symphysis Medical
2nd December, 2019
In November, the SymPhysis Medical team completed one of the most successful startup incubators in the world, YES!Delft Validation Lab. The Validation Lab is an eight-week pressure cooker to support...
Read more
Posted in News by Symphysis Medical
2nd December, 2019
SymPhysis Medical will be collaborating with Dr. Conor Judge, a Wellcome Trust-Health Research Board ICAT Fellow and Nephrology Specialist Registrar, to investigate the commercial feasibility of an innovative peritoneal dialysis...
Read more
Affects ~90% of patients with mesothelioma.
Affects ~ 35% of patients with lung cancer.
Affects ~ 16% of patients with breast cancer.
Affects ~ 11% of patients with lymphoma.
